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To determine factors associated with mutations in the Pneumocystis carinii dihydropteroate
synthase (DHPS) gene, a prospective study of human immunodeficiency virus (HIV)–infected
patients with confirmed P. carinii pneumonia was conducted in Atlanta, Seattle, and San
Francisco. Clinical information was obtained from patient interview and chart abstraction.
DHPS genotype was determined from DNA sequencing. Overall, 76 (68.5%) of 111 patients
had a mutant DHPS genotype, including 22 (81.5%) of 27 patients from San Francisco. In
multivariate analysis, sulfa or sulfone prophylaxis and study site were independent predictors
of a mutant genotype. Fourteen (53.8%) of 26 patients who were newly diagnosed with HIV
infection and had never taken prophylaxis had a mutant genotype. The significance of geographic location as a risk factor for mutant genotype and the high proportion of mutant
genotypes among persons never prescribed prophylaxis, including those newly diagnosed with
HIV infection, provide indirect evidence that these mutations are transmitted from person to
person either directly or through a common environmental source.

In 1981, the first reports of Pneumocystis carinii pneumonia
(PCP), a previously rare disease, heralded the onset of the AIDS
epidemic [1, 2]. Throughout much of the epidemic, PCP has
remained the most common AIDS-defining opportunistic infection in the United States and a significant cause of pneumonia
in human immunodeficiency virus (HIV)–infected persons [3–7].
Although the incidence of PCP has declined dramatically as a
result of P. carinii prophylaxis and, more recently, combinations
of antiretroviral therapies, the number of HIV-infected persons
potentially at risk for the disease remains substantial [8].
Since 1989, P. carinii prophylaxis has been recommended for
HIV-infected persons with a CD4 cell count !200 cells/mL, with
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oral candidiasis regardless of CD4 cell count, and after an episode of PCP [9]. Current guidelines recommend trimethoprimsulfamethoxazole (TMP-SMZ) as first-line prophylaxis against
P. carinii [10]. Dapsone is an alternative prophylaxis choice for
persons who are allergic to or intolerant of TMP-SMZ [10].
The widespread use of TMP-SMZ for P. carinii prophylaxis
has been implicated in the increases in TMP-SMZ–resistant bacteria that have been reported in HIV-infected patients [11].
Chronic use of prophylaxis has also raised concerns about the
possible selection of drug resistant P. carinii. The lack of a standardized culture system for human P. carinii has, however, limited
our ability to confirm drug resistance in P. carinii. In animals,
the antipneumocystis activity of TMP-SMZ is almost entirely
attributable to SMZ, an inhibitor of the P. carinii dihydropteroate
synthase (DHPS) gene, and not to TMP, an inhibitor of the
dihydrofolate reductase (DHFR) gene [12–16]. Dapsone, a sulfone, is also a DHPS inhibitor. In several microorganisms, sulfa
or sulfone resistance has been demonstrated to result from specific
point mutations in that organism’s DHPS gene [17–24]. Several
recent studies have demonstrated similar point mutations in the
P. carinii DHPS gene and have found an association between
the use of sulfa or sulfone drugs for P. carinii prophylaxis and
DHPS mutations [25–27]. Another recent study found mutations
in the DHPS gene but not in the DHFR gene in patients using
sulfa or sulfone drugs [28]. These studies, however, are limited,
because the number of HIV-infected patients prescribed sulfa or
sulfone prophylaxis was small, ranging from 2 to 29 patients.
Consequently, detailed statistical analysis to determine whether
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Patients and Methods
Patients. Patients were HIV-infected adults (>18 years old)
with confirmed PCP hospitalized at 1 of 9 institutions in 3 geographically distinct cities (Grady Memorial Hospital and Atlanta
Veterans Affairs Medical Center, Atlanta; University of Washington Medical Center, Harborview Medical Center, Swedish Hospital
Medical Center, Providence Medical Center, Virginia Mason Medical Center, and Group Health Cooperative Central and Eastside
Hospitals, Seattle; San Francisco General Hospital, San Francisco). Patients were consecutive patients at each institution who
consented to a patient interview conducted at the time of hospitalization and a medical chart abstraction performed >6 weeks
after the date of discharge.
Patient interview. Trained study personnel conducted patient
interviews, using a standardized questionnaire. The patient interview obtained specific information on demographic and clinical
data and included details on the patient-reported use of sulfa or
sulfone drugs for P. carinii prophylaxis in the 3 months preceding
PCP diagnosis. The questionnaires used in Atlanta and San Francisco were identical and contained a specific question that asked
whether the patient had ever taken TMP-SMZ for P. carinii prophylaxis. The questionnaire used in Seattle was similar to those in
Atlanta and San Francisco but did not include the specific question
that asked whether the patient had ever taken TMP-SMZ.
Medical chart abstraction. Trained study personnel performed
medical chart abstraction, using a standardized abstraction form.
Similar to the patient interview, the chart abstraction obtained
specific information on demographic and clinical data. It also documented the date of the first positive HIV test result, prior episode(s) of PCP, and the date and result of the most recent CD4
cell count. In addition, the abstraction contained details on the
provider prescription of sulfa or sulfone drugs for P. carinii prophylaxis in the 3 months preceding PCP diagnosis. Neither the
patient interview nor the chart abstraction obtained details concerning the duration of sulfa or sulfone prophylaxis.
Sulfa or sulfone prophylaxis. For the univariate and multivariate
analyses, criteria for sulfa or sulfone prophylaxis included patient
report of having taken TMP-SMZ or dapsone for prophylaxis at
any time, patient report of taking TMP-SMZ or dapsone in the 3
months before PCP diagnosis, or chart abstraction noting TMP-SMZ
or dapsone prophylaxis prescription in the 3 months before PCP
diagnosis. Additional analyses examined prophylaxis according to
the source of information (patient interview or chart abstraction)
and the timing of prophylaxis (ever or in the past 3 months).

P. carinii specimens. P. carinii specimens were obtained as part
of routine diagnostic procedures. The procedure for specimen processing, DNA purification, polymerase chain reaction (PCR) amplification, and DNA sequencing have been described in detail
elsewhere [29]. After clinical use, the remaining portion of the specimen was preserved with an equal volume of absolute ethanol and
stored at 47C for DNA extraction. Specimens were shipped to the
Centers for Disease Control and Prevention for analysis, including
DNA extraction that was performed using the Wizard Genomic
DNA Purification Kit (Promega, Madison, WI). PCR amplification was performed at the DHPS locus by use of published primers
[25, 30]. DNA sequencing was performed using dye terminator
chemistry (ABI PrismTM Big DyeTM Terminator Cycle Sequencing
Ready Reaction Kit; PE Applied Biosystems, Foster City, CA).
Analysis of the sequenced DNA was performed using Sequence
Navigator (version 1.0.1, PE Applied Biosystems) and the Wisconsin Package (version 10.1; Genetics Computer Group, Madison,
WI).
P. carinii DHPS genotype. For the univariate and multivariate
analyses, the wild-type P. carinii DHPS genotype was defined as the
DNA sequence observed in P. carinii specimens from other mammalian species and from humans before 1995 [25–27, 30]. A mutant
P. carinii DHPS genotype was defined as any DNA sequence that
differed from the wild-type sequence. The observed DHPS mutations
were all nonsynonymous changes that resulted in amino acid substitutions at either amino acid positions 55 or 57 and were identical
to the mutations reported elsewhere [25]. Patient specimens with
multiple DHPS genotypes that included >1 mutant genotype were
classified as mutant DHPS genotypes in the analyses.
Statistical analysis. Statistical analysis was performed using
SAS (version 6.12; SAS Institute, Cary, NC). Univariate analyses
were performed using the x2 or Fisher’s exact (2-tailed) tests. Odds
ratios and 95% confidence intervals were calculated to assess the
univariate risk for having a mutant P. carinii DHPS genotype.
Clinical variables significant at the P ! .10 level were included in
multivariate logistic regression analyses. P ! .05 was used to define
statistical significance.

Results
Patients. From January 1996 to March 1999, 118 HIVinfected patients were diagnosed with PCP and consented to a
patient interview and medical chart abstraction. Of these 118
patients, 111 (94.1%) had the P. carinii DHPS locus successfully
sequenced and were included in this analysis (table 1). Fortyeight patients were diagnosed with PCP in Atlanta, 36 in Seattle, and 27 in San Francisco. Patients had a mean age of 39.0
years. Most of the patients were male. All major racial, ethnic,
and HIV risk groups were represented.
The date of the first positive HIV test was documented in
the chart for 82 patients. These patients were known to be HIV
infected for a median of 17 months (mean, 38 months) before
the PCP diagnosis that was examined in this analysis. The duration of known HIV infection varied greatly (range, 0–150
months) and included 26 persons who were newly diagnosed
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factors other than prophylaxis also predict mutations in the P.
carinii DHPS gene was not performed. In addition, these studies
used P. carinii specimens from single institutions or from institutions from the same geographic region. We have shown elsewhere that geographic location appears to be an important determinant of DHPS genotype [29].
Therefore, the objective of the present study was to determine
the factors that are associated with mutations in the P. carinii
DHPS gene, by use of multivariate analytical techniques, from
a large prospective study of HIV-infected patients with confirmed PCP from geographically distinct regions.
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Table 1. Demographic and clinical characteristics of 111 human immunodeficiency virus (HIV)–infected patients diagnosed with Pneumocystis carinii pneumonia (PCP).

Study site
Atlanta
Seattle
San Francisco
Age, years
Median (range)
Mean (5SE)
Sex
Male
Female
Race/ethnicity
Black, non-Hispanic
White, non-Hispanic
Hispanic
Asian/Pacific Islander
Other
HIV risk factor
a
MSM
Heterosexual contact
IDU
Other
Duration of known HIV infection, months (n p 82)
Median (range)
Mean (5SE)
CD4 cell count, cells/mL (n p 106)
Median (range)
Mean (5SE)
Prior PCP
No
Yes
Sulfa or sulfone prophylaxis
Yes
No

HIV-infected
patients with PCP
48 (43.2)
36 (32.4)
27 (24.3)
38.0 (22.8–63.4)
39.0 (0.7)
99 (89.2)
12 (10.8)
55
40
9
3
4

(49.5)
(36.0)
(8.1)
(2.7)
(3.6)

66
31
13
1

(59.5)
(27.9)
(11.7)
(0.9)

17 (0–150)
38 (5)
23 (0–328)
58 (11)
78 (70.3)
33 (29.7)
71 (64.0)
40 (36.0)

NOTE. Data are no. (%) unless otherwise indicated. MSM, men who have
sex with men; IDU, injection drug use.
a
MSM includes persons who report both men who have sex with men and
IDU.

with HIV infection and 5 patients who were known to be HIV
infected for more than a decade.
CD4 cell counts were documented in the chart for 106 patients. The median CD4 cell count was 23 cells/mL (mean, 58
cells/mL). Eight patients had a CD4 cell count 1200 cells/mL
(range, 203–328 cells/mL), obtained a median of 98 days (range
2–442 days) before diagnosis of PCP. Thirty-three patients
(29.7%) reported a prior episode of PCP. Overall, 71 patients
(64.0%) had sulfa or sulfone prophylaxis use.
P. carinii DHPS genotype. Most of the P. carinii DHPS
genotypes were mutant (table 2). Overall, only 35 of the PCP
specimens (31.5%) had the wild-type genotype as the sole genotype. The remaining 76 specimens (68.5%) contained >1 mutant
genotype, either as the sole genotype (n p 63 ) or as part of a
mixed infection (n p 13). The most frequent genotype observed
was a double mutant, with an alaninerthreonine substitution
at amino acid position 55 and a serinerproline substitution at
amino acid position 57. This genotype was seen in 60 of the
specimens (54.1%); in 55 specimens, it was the sole genotype,

and in 5 specimens, it was part of a mixed infection. The second
most frequent genotype observed was the wild type. Combined,
these 2 genotypes were seen alone or as part of a mixed infection
in 192% of the PCP specimens examined.
Overall, the proportion of mutant P. carinii DHPS genotypes
remained stable over the study period. In the first half of the
study (1996–97), 38 (67.9%) of 56 of the specimens had a mutant genotype, whereas, in the second half of the study (1998
to March 1999), 38 (69.1%) of 55 of the specimens had a mutant
genotype (P p .95).
Association between clinical characteristics and P. carinii
DHPS genotype. In univariate analysis, sulfa or sulfone prophylaxis, prior PCP, and study site were all associated with an
increased risk for having a mutant P. carinii DHPS genotype
(table 3). Patients who had sulfa or sulfone prophylaxis use
were more likely to have a mutant genotype than were patients
who did not. Similarly, patients with a prior episode of PCP
were more likely to have a mutant genotype than were patients
without prior PCP. Interestingly, patients who were diagnosed
with PCP in either San Francisco or Seattle were also more
likely to have a mutant P. carinii genotype than were patients
who were diagnosed with PCP in Atlanta.
In multivariate logistic regression analyses, sulfa or sulfone
prophylaxis and study site were independent risk factors for
having a mutant P. carinii DHPS genotype (table 4). Because
prophylaxis and prior PCP were highly correlated, we examined
the impact of prior PCP on sulfa or sulfone prophylaxis in
models that excluded and included prior PCP. In both models,
patients who had sulfa or sulfone prophylaxis use were more
likely to have a mutant genotype than were patients who did
not. In addition, patients who were diagnosed with PCP in
either San Francisco or Seattle were also more likely to have
a mutant genotype than were patients who were diagnosed with
PCP in Atlanta in both models. Separate analyses that examined different definitions for sulfa or sulfone prophylaxis,
that excluded mixed genotypes, and that compared the wild
type with the double mutant genotype (the 2 most frequent
genotypes observed) yielded similar results to those presented.
Table 2.
Pneumocystis carinii dihydropteroate synthase (DHPS)
genotype in 111 human immunodeficiency virus–infected patients diagnosed with P. carinii pneumonia (PCP).

DHPS genotype
Wild type
1
Mutation(s)
2
3
4
Mixed
5
6
7
8

Amino acids

HIV-infected
patients with PCP,
no. (%)

Thr 55, Pro 57

35 (31.5)

Ala 55, Pro 57
Thr 55, Ser 57
Ala 55, Ser 57

6 (5.4)
2 (1.8)
55 (49.5)

Thr 55, Pro 57/Ser 57
Thr 55/Ala 55, Pro 57/Ser 57
Thr 55/Ala 55, Pro 57
Ala 55, Pro 57/Ser 57

4
3
4
2

(3.6)
(2.7)
(3.6)
(1.8)
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Table 3. Univariate analysis of demographic and clinical factors associated with mutant
Pneumocystis carinii dihydropteroate synthase (DHPS) genotype in 111 human immunodeficiency virus (HIV)–infected patients diagnosed with P. carinii pneumonia (PCP).

Factor
Study site
San Francisco
Seattle
Atlanta
Age, per 10 years
Sex
Male
Female
Race/ethnicity
Black, non-Hispanic
White, non-Hispanic
Other
HIV risk factor
Men who have sex with men
Injection drug use
Other
HIV infection, per 6 months
CD4 cell count, per 50 cells/mL
Prior PCP
Yes
No
Sulfa or sulfone prophylaxis
Yes
No

22/27 (81.5)
28/36 (77.8)
26/48 (54.2)

Odds ratio

95% confidence
interval

P

3.7
3.0
1.0 (Reference)
0.7

1.2–11.5
1.1–7.8

.02

0.4–1.2

.19

67/99 (67.7)
9/12 (75.0)

0.7
1.0 (Reference)

0.2–2.8

.75

35/55 (63.6)
30/40 (75.0)
11/16 (68.8)

0.8
1.4
1.0 (Reference)

0.2–2.6
0.4–4.9

.50

50/66 (75.8)
8/13 (61.5)
18/32 (56.2)

2.4
1.2
1.0 (Reference)
1.01
0.9

1.0–6.0
0.3–4.6

.13

1.0–1.2
0.7–1.3

.10
.72

28/33 (84.8)
48/78 (61.5)

3.5
1.0 (Reference)

1.2–10.1

.02

57/71 (80.3)
19/40 (47.5)

4.5
1.0 (Reference)

1.9–10.6

!.001

Sulfa or sulfone prophylaxis according to study site. When
stratified by study site, the association between sulfa or sulfone
prophylaxis and P. carinii DHPS genotype was lost for patients
residing in San Francisco (figure 1). Similar to Atlanta (70.0%)
and Seattle (88.0%), patients diagnosed with PCP in San Francisco who had sulfa or sulfone prophylaxis use had a high
proportion of mutant genotypes (87.5%); however, patients in
San Francisco who denied sulfa or sulfone prophylaxis use and
whose charts failed to document sulfa or sulfone prophylaxis
prescription also had a surprisingly high proportion of mutant
genotypes (72.7%). The greater proportion of mutant DHPS
genotypes in these patients accounted for the observation that
sulfa or sulfone prophylaxis was no longer significantly associated with P. carinii DHPS genotype among patients residing
in San Francisco.
P. carinii DHPS genotype in patients newly diagnosed with HIV
infection. Twenty-six of 82 patients for whom a precise date
for the first positive HIV test was available were newly diagnosed
with HIV infection at the same time as or immediately before
the diagnosis of PCP. Importantly, none of the 26 patients reported use of any P. carinii prophylaxis (including sulfa or sulfone
drugs) or a prior episode of PCP during the patient interview.
Despite the absence of sulfa or sulfone prophylaxis use, 14 of
the 26 patients (53.8%) had a mutant P. carinii DHPS genotype
(table 5). Among the study sites, the proportion of patients with
newly diagnosed HIV infection and a mutant genotype was lowest in Atlanta (38.5%) and highest in San Francisco (70.0%),
paralleling the proportion of mutant genotype in the overall co-

hort (Atlanta, 54.2%; San Francisco, 81.5%; table 3). At each
study site, as the known duration of HIV infection increased,
the proportion of mutant genotypes also increased. The only
exception was among the 5 patients who were known to be HIV
infected for 110 years; of these 5 patients (all residing in Atlanta),
only 2 (40.0%) had a mutant genotype.
Discussion
In our prospective study conducted in 3 geographically distinct cities, we found in multivariate analyses that sulfa or sulfone prophylaxis and study site were independent risk factors
for having a mutant P. carinii DHPS genotype. Interestingly,
we found that residence in San Francisco or Seattle was a strong
predictor for having a mutant genotype and, when stratified
by study site, sulfa or sulfone prophylaxis was no longer significantly associated with mutant genotype for patients residing
in San Francisco. We also found that more than half the patients who were newly diagnosed with HIV infection—none of
whom reported prior use of any P. carinii prophylaxis—had a
mutant genotype.
Sulfa or sulfone prophylaxis was an independent risk factor
for having a mutant P. carinii DHPS genotype. Overall, 57
(80.3%) of 71 patients who received sulfa or sulfone prophylaxis
had a mutant genotype. These results are consistent with previously published reports and confirm these prior observations
in a multivariate analysis that examined a substantially larger
group of patients with prophylaxis use [25, 27, 28]. Kazanjian
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Mutant P. carinii DHPS genotype
Model 1
Predictor
Study site
San Francisco
Seattle
Sulfa or sulfone prophylaxis
Yes
Prior PCP
Yes
NOTE.

Model 2

AOR (95% CI)

P

AOR (95% CI)

P

4.8 (1.4–16.2)
3.1 (1.1–8.7)

.01
.04

5.0 (1.5–17.2)
3.2 (1.1–9.2)

.01
.03

5.2 (2.1–12.9)

!.01

3.9 (1.4–10.5)

!.01

—

2.2 (0.6–7.4)

.21

AOR, adjusted odds ratio; CI, confidence interval.

et al. [25] found DHPS mutations in 5 (71%) of 7 HIV-infected
patients whose medical and pharmacy records documented
sulfa or sulfone prophylaxis use for >1 month during the 4
months preceding PCP diagnosis. Helweg-Larsen et al. [27]
found mutations in 18 (62%) of 29 patients who were exposed
to >1 week of a sulfa drug at any time after the diagnosis of
HIV infection. Finally, Ma et al. [28] found mutations in 11
(84.6%) of 13 patients with prior sulfa or sulfone prophylaxis
use. Our results, combined with these studies, make clear the
association between sulfa or sulfone prophylaxis and DHPS
mutations. What is unclear, however, is which specific feature(s)
of sulfa or sulfone prophylaxis are most crucial to the selection
of DHPS mutations. Unfortunately, each of these studies used
a different definition of sulfa or sulfone prophylaxis, which
makes it impossible for direct comparisons to be made. In addition, none of the studies, including the present one, examined
the impact of potentially important features, such as the duration of sulfa or sulfone prophylaxis, on the risk of DHPS
mutations. Consequently, which specific feature of sulfa or sulfone prophylaxis is associated with risk of DHPS mutations is
an important but unanswered question.
The clinical significance of DHPS mutations and, specifically,
whether their presence implies the existence of resistant P. carinii
and resistance to TMP-SMZ– or dapsone-containing PCP
treatment regimens is unclear at present. Helweg-Larsen et al.
[27] found a significantly lower 3-month survival among patients with DHPS mutations in a multivariate analysis that
controlled for patient age, CD4 cell count, and PaO2. Whether
this finding establishes the presence of TMP-SMZ– or dapsoneresistant P. carinii could not be answered in their analysis and
is currently being investigated in our cohort.
Study site was also an independent risk factor for having a
mutant P. carinii DHPS genotype. Patients diagnosed with PCP
in either San Francisco or Seattle were more likely to have a
mutant genotype than were persons diagnosed with PCP in
Atlanta, even after controlling for prior PCP and sulfa or sulfone prophylaxis. This result confirms our earlier report that

demonstrated a significant association between DHPS genotype
and study city, an association that was stronger between DHPS
genotype and city of PCP diagnosis than city/place of birth
[29]. Importantly, the current analysis extends our earlier one
by controlling for important predictors of mutant genotypes,
such as prior PCP and sulfa or sulfone prophylaxis.
Residence in San Francisco appeared to be a strong predictor
for having a mutant P. carinii DHPS genotype. Overall, 81.5%
of the patients residing in San Francisco had a mutant genotype. Consequently, sulfa or sulfone prophylaxis was no longer
significantly associated with mutant genotype for patients residing in San Francisco. We believe that this result is valid for
several reasons. First, the proportion of mutant genotypes from
San Francisco in this analysis is similar to our earlier analysis
that examined DHPS genotypes without clinical information
in which 54 (81.8%) of the 66 patient specimens from San Francisco had a mutant genotype [29]. Thus, the high proportion
of mutant genotypes in San Francisco is unlikely to be the
result of chance due to a small sample size. Second, the proportion of patients who had a mutant DHPS genotype despite
being classified as not on prophylaxis was consistent using different instruments and different time points. In San Francisco,
one study nurse performed all patient interviews, and a different
study nurse conducted all chart abstractions; each was blinded
to the results obtained by the other. Thus, we believe that the
high proportion of mutant genotypes in persons classified as
not on prophylaxis is unlikely to be the result of misclassification of these patients. In fact, 10 of the 11 San Francisco

Figure 1. Proportion of mutant Pneumocystis carinii dihydropteroate synthase (DHPS) genotypes according to sulfa or sulfone prophylaxis and site of P. carinii pneumonia (PCP) diagnosis in the 111
human immunodeficiency virus–infected patients diagnosed with PCP.
White bars, Persons who reported sulfa or sulfone prophylaxis use or
persons whose chart documented sulfa or sulfone prophylaxis prescription. Black bars, Persons who denied sulfa or sulfone prophylaxis use
and whose chart failed to document sulfa or sulfone prophylaxis prescription. Overall, all 3 cities combined; Atl, Atlanta; Sea, Seattle; SF,
San Francisco. *P ! .05 for comparison of proportions.
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Site of PCP diagnosis

Known duration
of HIV

Atlanta

Seattle

San Francisco

Overall

Newly diagnosed
!5 Years
5–10 Years
110 Years
Overall

5/13 (38.5)
9/17 (52.9)
6/6 (100)
2/5 (40.0)
22/41 (53.7)

2/3 (66.7)
6/6 (100)
5/5 (100)
NA
13/14 (92.9)

7/10 (70.0)
8/10 (80.0)
7/7 (100)
NA
22/27 (81.5)

14/26 (53.8)
23/33 (69.7)
18/18 (100)
2/5 (40.0)
57/82 (69.5)

NOTE Data are no. of mutant DHPS genotypes / total no. of DHPS genotypes (%). NA, not applicable.

patients who denied ever using TMP-SMZ were newly HIV
diagnosed, and 7 of these 10 had a mutant genotype.
More than half the patients (14 of 26) who were newly diagnosed with HIV infection, none of whom reported prior use
of any P. carinii prophylaxis (including sulfa or sulfone prophylaxis) had a mutant genotype. Potentially, these people
could have received a sulfa drug previously for reasons unrelated to HIV disease. Unfortunately, our patient interview and
chart abstraction were not structured to detect this possibility;
however, Kazanjian et al. [25], Helweg-Larsen et al. [27], and
Ma et al. [28] also detected mutant DHPS genotypes in persons
never exposed to sulfa or sulfone drugs. In these studies, 2
(28.6%) of 7 patients, 13 (10.3%) of 123 patients, and 3 (20.0%)
of 15 patients, respectively, who were never exposed to sulfa
or sulfone drugs had a mutant DHPS genotype, which are lower
percentages than those observed in this study. Because the natural reservoir for human P. carinii remains unknown at present,
the potential impact of sulfa or sulfone use on this reservoir
cannot be determined.
The findings that geographic region predicts mutant P. carinii
DHPS genotypes, that mutant genotypes are seen in persons who
deny prophylaxis use, and especially that mutant genotypes are
seen in more than half the patients who were newly diagnosed
as HIV-infected raise interesting questions regarding the epidemiology and transmission of human P. carinii. Whether PCP in
humans is a result of reactivation of latent infection or recent
acquisition is unclear [31, 32]. Keely et al. [33] examined P. carinii
specimens from 10 patients who each had 2 episodes of PCP >3
months apart and sequenced the large subunit of mtrRNA. In
half the cases, the mtrRNA sequences observed in the second
episode differed from that observed in the first, which suggests
that the second episode of PCP in these individuals was the result
of a new, recent infection.
Whether the reservoir of human P. carinii resides solely in
humans or also in the environment remains unclear. Recently,
a case-control study found that HIV-infected patients hospitalized with PCP were significantly more likely to have gardened, camped, or hiked in the 6 months before PCP diagnosis,

compared with the age- and CD4 cell count–matched HIVinfected control patients hospitalized for a reason other than
pneumonia, which suggests that recent soil exposure may be a
potential source of P. carinii [34]. Our observations from this
study are consistent with the possibility of recent acquisition
and transmission of these mutant P. carinii DHPS genotypes,
either from person-to-person or from one person to another
through a common environmental source. In either case, the
presence of mutant DHPS genotypes in persons never prescribed sulfa or sulfone prophylaxis argues strongly for the
importance of humans in the transmission of this disease.
In summary, this prospective study found that sulfa or sulfone prophylaxis and city of PCP diagnosis were independent
risk factors for having a mutant P. carinii DHPS genotype. The
significance of city of PCP diagnosis and the finding of mutant
genotypes in more than half the patients who were newly diagnosed with HIV infection, none of whom report having ever
taken any prophylaxis, raises interesting questions concerning
the epidemiology and transmission of human P. carinii that
warrant further investigation.
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